PNH Clinical Trial
Official title:
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
Verified date | May 2022 |
Source | CANbridge Life Sciences Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single site, single dose escalation study in healthy subject with CAN106. The study is to assess the safety and tolerability of single escalating doses of CAN106; to characterize the PK and PD profile of CAN106; and to evaluate the immunogenicity of CAN106 injection.
Status | Completed |
Enrollment | 31 |
Est. completion date | November 30, 2021 |
Est. primary completion date | November 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 45 Years |
Eligibility | Inclusion Criteria: - Subjects must be able to understand and provide informed consent. - Males or females, between 21 and 45 years of age, inclusive; - Body mass index must be within the range of 18.5 to 32.0 kg/m2; - 12-lead electrocardiogram (ECG) within normal limits with no clinically significant abnormalities in the opinion of the Investigator; - Systolic blood pressure =140 mmHg and a diastolic blood pressure of = 90 mmHg after 5 minutes with supine rest; - non-pregnancy - meningococcal vaccinations for at least 2 weeks before dosing Exclusion Criteria: - Disease or conditions interfere with participating the trial - Active serious mental illness or psychiatric disorder - clinically relevant abnormal test results in hepatic function - unacceptable CBC lab test - asymptomatic complement deficiency - Any other clinical safety laboratory test - HIV, HBV, HCV positive - Alcohol and drug abuse - etc. |
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
CARE Pharma Shanghai Ltd. |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of subjects with dose-limiting toxicity (DLTs) | TEAEs will be categorized as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria.
a DLT is defined as one subject with a Grade 3 AE or higher, that are assessed as drug-related by the site investigator. |
6-months after dosing | |
Primary | Incidence of adverse events (AEs) | An AE is defined as any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. | 6-months after dosing | |
Primary | Incidence of severe adverse events (SAEs) | Any untoward medical occurrence that at any dose:
Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, or Is a congenital anomaly/birth defect. (ICH E6 (R2)) |
6-months after dosing | |
Secondary | PK parameters - tmax | time to reach maximum of concentration (days) | 6-months after dosing | |
Secondary | PK parameters-Cmax | peak plasma concentration | 6-months after dosing | |
Secondary | PK parameters - AUC0-t | Area under the plasma concentration versus time curve to the last visit (AUCt) | 6-months after dosing | |
Secondary | PK parameters - t1/2 | terminal elimination half-life | 6-months after dosing | |
Secondary | PD endpoints-free C5 | maximal change from baseline in free C5 concentrations at each of scheduled post baseline assessment time-points (µg/ml); | 6-months after dosing | |
Secondary | PD endpoints-CH50 | maximal change from baseline total complement activity (CH50) at each of scheduled post baseline assessment time-points (%); | 6-months after dosing | |
Secondary | PD endpoints-total C5 | meausure the absolute change from baseline in total C5 concentrations at each of scheduled post baseline assessment time-points (µg/ml); | 6-months after dosing | |
Secondary | Immunogenicity | Anti-drug Antibody (ADA) titers | 6-months after dosing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04725812 -
Complement Regulation to Undo Systemic Harm in Preeclampsia
|
Phase 2 | |
Completed |
NCT02598583 -
Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05539248 -
A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03460301 -
Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH
|
N/A | |
Completed |
NCT01412047 -
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
|
N/A | |
Completed |
NCT02605993 -
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Terminated |
NCT04702568 -
A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT05337683 -
A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
|
||
Active, not recruiting |
NCT03531255 -
Pegcetacoplan Long Term Safety and Efficacy Extension Study
|
Phase 3 | |
Not yet recruiting |
NCT06449001 -
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
|
Phase 3 | |
Completed |
NCT03593200 -
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
|
Phase 2 | |
Completed |
NCT05884060 -
Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
|
||
Available |
NCT05982938 -
Danicopan Early Access Program
|